TS
AMAM

Thomas Steyer’s Ambrx Biopharma Inc AMAM Stock Holding History

Thomas Steyer’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,269,000
Closed -$37.3M – 182
2023
Q2 		$37.3M Buy
2,269,000
+1,908,000
+529% +$24M 0.19% 73
2023
Q1 		$3.22M Buy
+361,000
New +$1.81M 0.02% 132

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Thomas Steyer's AMAM Position: Q3 2023 in Review

Thomas Steyer sold out of Ambrx Biopharma Inc (AMAM) in Q3 2023, closing a stake of 2,269,000 shares — an estimated $37.3M sold.

Thomas Steyer first reported a position in AMAM in Q1 2023 and held it in 2 quarters. The position peaked at $37.3M in Q2 2023. 44 funds tracked by Wall St. Rank hold AMAM as of Q3 2023.

  • Thomas Steyer reported no remaining Ambrx Biopharma Inc position as of Q3 2023 after selling out during the quarter.
  • Thomas Steyer sold 2,269,000 Ambrx Biopharma Inc shares in Q3 2023, an estimated $37.3M.
  • Thomas Steyer first reported a position in Ambrx Biopharma Inc in Q1 2023 and held it in 2 quarters.
  • Thomas Steyer's Ambrx Biopharma Inc position peaked at $37.3M in Q2 2023.
  • 44 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2023.

Based on Farallon Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.